Johnson & Johnson's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Leadership changes can affect company strategy and stock performance over time.
New deals expand the company's products but reduce earnings per share by $0.64 in 2026.
Major legal settlement reduces future cash and affects company finances significantly.
Quarterly results show if the company is making money and growing as expected.
Shareholders approved leadership and compensation, showing trust in company direction.
Quarterly financial reports let investors track company progress throughout the year.
Stocky reads Johnson & Johnson's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Johnson & Johnson's most recent tracked filing was a 8-K on 4 Aug 2026: Jennifer Taubert retires as Innovative Medicine leader.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.